Moderna Therapeutics, a biotech unicorn valued at more than $7.5 billion, is preparing for an initial public offering that could come as early as this winter, according to people familiar with the process.
The Cambridge, Mass.-based company, which has doggedly stayed private amid a boom of biotech IPOs, has recruited Goldman Sachs, J.P. Morgan, and Morgan Stanley to manage its Wall Street debut, the people said.
Moderna will soon begin one-on-one meetings with investors to test the waters for an IPO, according to the individuals familiar with the plans, who spoke on condition of anonymity because the process is confidential. It is seeking a valuation of more than $10 billion, they said, which would mark the largest IPO in biotech history. The process is in its early stages and could run into delays, they said.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
